Dexamethasone-Induced Tumor Lysis Syndrome in Lymphoma

Risk Factors and Prevention

Patients with high-grade non-Hodgkin lymphoma, particularly Burkitt's lymphoma and lymphoblastic lymphoma, are at higher risk for developing TLS after dexamethasone administration, according to the National Comprehensive Cancer Network 1
The European Society for Medical Oncology recommends that patients with bulky disease (especially lymph nodes >5 cm) should be considered high-risk for TLS 2
Elevated LDH (>2 times upper normal limit) is a risk factor for TLS, as reported by Haematologica 3
Pre-existing renal impairment is a risk factor for TLS, as noted by Haematologica 3
Elevated uric acid levels (>8 mg/dL in children, >10 mg/dL in adults) are a risk factor for TLS, according to Haematologica 3

For low-risk patients, the American Society of Clinical Oncology recommends oral allopurinol (100 mg/m² three times daily, maximum 800 mg/day), adequate hydration, and urine alkalinization to prevent TLS 3
For high-risk patients, Haematologica suggests rasburicase (0.20 mg/kg/day) administered at least four hours before starting dexamethasone, inpatient monitoring, aggressive hydration, and avoidance of concomitant allopurinol with rasburicase 3
The National Comprehensive Cancer Network recommends monitoring patients receiving dexamethasone for lymphoma for serum electrolytes (potassium, phosphorus, calcium), uric acid levels, renal function, and signs of tumor flare reactions 1
If TLS develops after dexamethasone administration, Haematologica recommends administering rasburicase and aggressive hydration 3
The European Society for Medical Oncology suggests managing tumor flare reactions with steroids for lymph node enlargement/inflammation and antihistamines for rash/pruritus 1

In cases with high tumor load, Annals of Oncology recommends considering administering prednisone 100 mg orally for several days as "prephase" treatment before starting more intensive therapy to avoid severe TLS 4
For patients with bulky lymphoma (>5 cm lymph nodes), special precautions are required to prevent TLS, as noted by Annals of Oncology 2

Failing to identify high-risk patients before administering dexamethasone is a clinical pitfall, as reported by Haematologica 3
Inadequate hydration or TLS prophylaxis in high-risk patients is a clinical pitfall, according to Haematologica 3

Tumor lysis syndrome (TLS) can occur spontaneously without chemotherapy, although it is rare compared to treatment-induced TLS, as documented in guidelines from Haematologica 5, 6, 7

Tumor lysis syndrome is a metabolic emergency characterized by rapid release of intracellular contents when tumor cells undergo lysis, leading to metabolic derangements 8
Metabolic derangements in TLS include hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia, which can lead to clinical complications 9
Potential clinical complications of TLS include renal insufficiency, cardiac arrhythmias, and seizures, highlighting the need for prompt management 10

Spontaneous TLS is a rare event that can develop in certain circumstances, more likely in tumors with high proliferative rates and large tumor burden, as reported in Haematologica 5, 7, 11
Tumors with high proliferation rates, such as Burkitt's lymphoma and B-ALL, are at higher risk for spontaneous TLS 6

Patients at higher risk for developing spontaneous TLS include those with hematologic malignancies, bulky disease, elevated LDH levels, and pre-existing conditions like renal dysfunction, as outlined in guidelines from Haematologica and Praxis Medical Insights 6, 7, 9
Risk assessment should be performed to identify high-risk patients, and prophylaxis based on risk level is recommended, including hydration, rasburicase, and allopurinol, according to Praxis Medical Insights 9

Monitoring of electrolytes, renal function, and uric acid levels is crucial in patients at risk for TLS, and aggressive intervention for established TLS, including possible dialysis, is necessary, as recommended by Praxis Medical Insights 9
The American Society of Clinical Oncology and Haematologica recommend prompt recognition and treatment of TLS to avoid delayed treatment and increased mortality 7, 9

Pre-existing renal dysfunction significantly worsens prognosis in patients with TLS, and patients with high tumor burden should be monitored even before starting treatment, as highlighted in guidelines from Praxis Medical Insights and Haematologica 7, 9